<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02104843</url>
  </required_header>
  <id_info>
    <org_study_id>AI443-115</org_study_id>
    <nct_id>NCT02104843</nct_id>
  </id_info>
  <brief_title>Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin</brief_title>
  <official_title>Effect of Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Therapy on the Pharmacokinetics of Rosuvastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose is to assess the effect of Daclatasvir (DCV)/Asunaprevir (ASV)/BMS-791325
      combination therapy on the exposure of Rosuvastatin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IND Number: 79,599/101,943

      Primary Purpose: Other - Phase 1 Clinical Pharmacology drug interaction study in healthy
      subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) of Rosuvastatin</measure>
    <time_frame>Day 1 (predose) to Day 5 (96 hours) and Day 15 (predose) to Day 19 (96 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T)) of Rosuvastatin</measure>
    <time_frame>Day 1 (predose) to Day 5 (96 hours) and Day 15 (predose) to Day 19 (96 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of Rosuvastatin</measure>
    <time_frame>Day 1 (predose) to Day 5 (96 hours) and Day 15 (predose) to Day 19 (96 hours)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration (Tmax) of Rosuvastatin</measure>
    <time_frame>Days 1 and 15 (predose through 96 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (T-HALF) of Rosuvastatin</measure>
    <time_frame>Days 1 and 15 (predose through 96 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F) of Rosuvastatin</measure>
    <time_frame>Days 1 and 15 (predose through 96 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712</measure>
    <time_frame>Day 15 (predose through 12 hours) and Days 13 and 14 pre-AM-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (predose) (Ctrough) of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712</measure>
    <time_frame>Day 15 (predose through 12 hours) and Days 13 and 14 pre-AM-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval [AUC(TAU)] of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712</measure>
    <time_frame>Day 15 (predose through 12 hours) and Days 13 and 14 pre-AM-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration (Tmax) of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712</measure>
    <time_frame>Day 15 (predose through 12 hours) and Days 13 and 14 pre-AM-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed plasma concentration at 12 hours after dosing in a pharmacokinetic (PK) profile (C12) of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712</measure>
    <time_frame>Day 15 (predose through 12 hours) and Days 13 and 14 pre-AM-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measured by incidence of Adverse events (AEs), Serious adverse events (SAEs) and AEs leading to discontinuation</measure>
    <time_frame>Days 1 through 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measured by results of vital sign measurements, Electrocardiogram (ECGs), physical examinations and clinical laboratory tests</measure>
    <time_frame>Days 1 through 19</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Arm 1: DCV/ASV/BMS-791325 FDC + BMS-791325 + Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: Rosuvastatin tablet orally on specified days
Treatment B: Daclatasvir, Asunaprevir and BMS-791325 Fixed dose combination (FDC) + BMS-791325 tablet orally on specified days
Treatment C: Daclatasvir, Asunaprevir and BMS-791325 FDC + BMS-791325 + Rosuvastatin tablet orally on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir, Asunaprevir and BMS-791325 FDC</intervention_name>
    <arm_group_label>Arm 1: DCV/ASV/BMS-791325 FDC + BMS-791325 + Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-791325</intervention_name>
    <arm_group_label>Arm 1: DCV/ASV/BMS-791325 FDC + BMS-791325 + Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>Arm 1: DCV/ASV/BMS-791325 FDC + BMS-791325 + Rosuvastatin</arm_group_label>
    <other_name>CrestorÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy subjects with no clinically significant deviations from normal in medical
             history, physical exam findings, 12 lead ECG measurements and clinical laboratory
             tests

          -  Females must be of non-childbearing potential

        Exclusion Criteria:

          -  Women of childbearing potential

          -  Any significant acute or chronic medical condition

          -  Inability to tolerate oral medications

          -  Inability to be venipunctured and/or tolerate venous access

          -  Abnormal liver function tests

          -  Current or recent (within 3 months of dosing) gastrointestinal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

